NAMS Menopause Certification Comprehensive
Certification Exam Updated 2026 | 1000+ Practice
Questions & Verified Answers | Ultimate
Menopause Society Board Exam Prep, Advanced
Women's Health Study Guide, Hormone Therapy
(HT), Perimenopause, Postmenopause, Vasomotor
Symptoms, Genitourinary Syndrome of Menopause
(GSM), Osteoporosis, Bone & Cardiovascular Health,
Sexual Medicine, Evidence-Based Clinical
Guidelines, Detailed Rationales
Question 1: A 52-year-old woman in the late menopausal transition reports
severe hot flashes, night sweats, and vaginal dryness. She has a history of
breast cancer treated with tamoxifen 5 years ago. Which of the following is the
MOST appropriate initial management strategy for her vasomotor symptoms?
A. Systemic estrogen-progestin therapy
B. Vaginal estrogen cream
C. Cognitive behavioral therapy (CBT) and non-hormonal pharmacologic options
D. Compounded bioidentical hormone therapy
CORRECT ANSWER: C. Cognitive behavioral therapy (CBT) and non-hormonal
pharmacologic options
Rationale: In a patient with a history of breast cancer, systemic hormone therapy is
generally contraindicated. While vaginal estrogen is considered low-risk for systemic
absorption, it is not the primary initial treatment for severe vasomotor symptoms (VMS).
The North American Menopause Society (NAMS) recommends non-hormonal options
such as CBT, hypnosis, and medications like SSRIs/SNRIs (e.g., paroxetine, venlafaxine)
as first-line management for VMS in breast cancer survivors. Compounded hormones
lack FDA approval and evidence for safety in this population.
Question 2: Which of the following stages of the STRAW +10 staging system is
characterized by persistent variability in menstrual cycle length of greater
than 7 days different from normal, occurring in the early menopausal
transition?
A. Stage -3a
B. Stage -3b
C. Stage -2
D. Stage -1
CORRECT ANSWER: C. Stage -2
Rationale: The STRAW +10 (Stages of Reproductive Aging Workshop) criteria define
the early menopausal transition (Stage -2) by persistent differences in menstrual cycle
length of 7 days or more. Stage -3a and -3b represent the late reproductive stage, with -
,3b showing a decrease in cycle length. Stage -1 is the late transition, characterized by
amenorrhea of 60 days or more.
Question 3: A 48-year-old woman presents with symptoms of vulvovaginal
atrophy. She is concerned about systemic absorption. What is the most
appropriate first-line topical treatment for her symptoms, according to NAMS
guidelines?
A. Ospemifene 60 mg daily
B. Prasterone (DHEA) 6.5 mg daily
C. Low-dose vaginal estradiol tablet (10 mcg)
D. Oral conjugated equine estrogens 0.3 mg daily
CORRECT ANSWER: C. Low-dose vaginal estradiol tablet (10 mcg)
Rationale: For genitourinary syndrome of menopause (GSM) without systemic
symptoms, low-dose vaginal estrogen (such as the 10 mcg estradiol tablet, 0.5 g
estradiol cream, or ring) is the first-line treatment. It is highly effective and has minimal
systemic absorption, making it safe for most women. Ospemifene and prasterone are
FDA-approved alternatives but are generally second-line. Oral estrogen is systemic and
not indicated for isolated GSM.
Question 4: A 55-year-old woman is 3 years post-menopausal and asks about
the benefits of hormone therapy (HT) for chronic disease prevention. Based on
the current NAMS position statement, what is the recommendation regarding
HT for primary prevention of coronary heart disease?
A. HT is recommended for primary prevention of CHD in all women over 50
B. HT is not recommended for primary prevention of CHD
C. HT is recommended only if initiated within 10 years of menopause
D. HT is recommended only for women with a family history of CHD
CORRECT ANSWER: B. HT is not recommended for primary prevention of CHD
Rationale: The NAMS position statement clarifies that hormone therapy should not be
used for the primary prevention of coronary heart disease. While the "timing
hypothesis" suggests potential benefits if started early (the "window of opportunity"), the
recommendation against primary prevention stands. However, HT may be considered
for symptom management in recently menopausal women without contraindications,
acknowledging possible coronary benefits in that specific subgroup but not as a
preventive strategy.
Question 5: Which of the following is considered an absolute contraindication
to the use of systemic menopausal hormone therapy?
A. History of deep vein thrombosis (DVT)
B. History of migraine with aura
C. History of hypertension
D. History of hypothyroidism
,CORRECT ANSWER: A. History of deep vein thrombosis (DVT)
Rationale: A history of venous thromboembolism (DVT or pulmonary embolism) is an
absolute contraindication to systemic hormone therapy due to the increased risk of
recurrence. Migraine with aura is a relative contraindication, while hypertension and
hypothyroidism are not contraindications but require monitoring and management.
Question 6: In a 53-year-old woman using a transdermal estradiol patch, what
is the primary advantage of the transdermal route over oral estrogen therapy
concerning venous thromboembolism (VTE) risk?
A. Lower risk of breast cancer
B. Lower risk of VTE due to avoiding first-pass hepatic metabolism
C. Higher efficacy for treating vasomotor symptoms
D. Better protection against osteoporosis
CORRECT ANSWER: B. Lower risk of VTE due to avoiding first-pass hepatic
metabolism
Rationale: Transdermal estrogen avoids the first-pass hepatic effect, which reduces the
production of clotting factors (e.g., prothrombin) and thus lowers the risk of VTE
compared to oral estrogens. This makes the transdermal route a preferred option for
women at elevated VTE risk (e.g., BMI > 30, smokers). It does not lower breast cancer
risk and has similar efficacy for VMS and bone health as oral forms when doses are
equivalent.
Question 7: A 60-year-old woman has been on combined continuous estrogen
and progestin therapy for 5 years. She is concerned about breast cancer risk.
According to NAMS, when should she be counseled to reevaluate her need for
continued hormone therapy?
A. Every 6 months
B. Annually
C. Every 2 years
D. Only when symptoms recur
CORRECT ANSWER: B. Annually
Rationale: NAMS recommends that the need for continued hormone therapy should be
assessed annually, weighing benefits and risks. There is no universal time limit, but the
risks (breast cancer, VTE, stroke) increase with age and duration of use, so annual
reassessment is critical for shared decision-making.
Question 8: Which of the following best describes the effect of the North
American Menopause Society's (NAMS) position on compounded bioidentical
hormone therapy?
A. Compounded hormones are superior to FDA-approved hormones due to their
"natural" composition.
B. Compounded hormones are preferred for women with allergies to standard
, preparations.
C. NAMS cautions against the use of compounded hormones due to lack of FDA
approval, standardized dosing, and safety/efficacy data.
D. NAMS recommends compounded hormones as first-line therapy for all menopausal
symptoms.
CORRECT ANSWER: C. NAMS cautions against the use of compounded
hormones due to lack of FDA approval, standardized dosing, and
safety/efficacy data.
Rationale: NAMS has issued a position statement cautioning against the use of
compounded bioidentical hormone therapy because of concerns regarding lack of
rigorous testing, variable potency, purity concerns, and absence of safety data. FDA-
approved bioidentical hormones (e.g., micronized 17β-estradiol) are preferred for their
consistent quality and proven efficacy.
Question 9: A 50-year-old woman in the late menopausal transition
experiences heavy menstrual bleeding. Which of the following is the most
appropriate initial diagnostic step to rule out endometrial pathology?
A. Empiric progestin therapy
B. Transvaginal ultrasound for endometrial stripe measurement
C. Hysteroscopy
D. Endometrial biopsy
CORRECT ANSWER: B. Transvaginal ultrasound for endometrial stripe
measurement
Rationale: In the evaluation of abnormal uterine bleeding in perimenopausal women,
transvaginal ultrasound is the recommended initial, non-invasive imaging modality to
measure endometrial thickness. An endometrial stripe < 4-5 mm is considered low risk
for malignancy (negative predictive value > 99%) in postmenopausal women, and a
threshold of ≤ 11 mm is often used for perimenopausal women. An endometrial biopsy
is indicated if the stripe is thickened or if risk factors persist.
Question 10: A postmenopausal woman on oral micronized progesterone (100
mg) reports significant drowsiness. What is the most appropriate management
strategy?
A. Discontinue the progesterone entirely
B. Switch to a synthetic progestin (e.g., medroxyprogesterone acetate)
C. Advise taking the dose at bedtime
D. Increase the dose to overcome the effect
CORRECT ANSWER: C. Advise taking the dose at bedtime
Rationale: Drowsiness is a common side effect of micronized progesterone due to its
metabolite, allopregnanolone, which has GABAergic effects. Taking the medication at
bedtime is an effective strategy to manage this side effect, converting it into a benefit
Certification Exam Updated 2026 | 1000+ Practice
Questions & Verified Answers | Ultimate
Menopause Society Board Exam Prep, Advanced
Women's Health Study Guide, Hormone Therapy
(HT), Perimenopause, Postmenopause, Vasomotor
Symptoms, Genitourinary Syndrome of Menopause
(GSM), Osteoporosis, Bone & Cardiovascular Health,
Sexual Medicine, Evidence-Based Clinical
Guidelines, Detailed Rationales
Question 1: A 52-year-old woman in the late menopausal transition reports
severe hot flashes, night sweats, and vaginal dryness. She has a history of
breast cancer treated with tamoxifen 5 years ago. Which of the following is the
MOST appropriate initial management strategy for her vasomotor symptoms?
A. Systemic estrogen-progestin therapy
B. Vaginal estrogen cream
C. Cognitive behavioral therapy (CBT) and non-hormonal pharmacologic options
D. Compounded bioidentical hormone therapy
CORRECT ANSWER: C. Cognitive behavioral therapy (CBT) and non-hormonal
pharmacologic options
Rationale: In a patient with a history of breast cancer, systemic hormone therapy is
generally contraindicated. While vaginal estrogen is considered low-risk for systemic
absorption, it is not the primary initial treatment for severe vasomotor symptoms (VMS).
The North American Menopause Society (NAMS) recommends non-hormonal options
such as CBT, hypnosis, and medications like SSRIs/SNRIs (e.g., paroxetine, venlafaxine)
as first-line management for VMS in breast cancer survivors. Compounded hormones
lack FDA approval and evidence for safety in this population.
Question 2: Which of the following stages of the STRAW +10 staging system is
characterized by persistent variability in menstrual cycle length of greater
than 7 days different from normal, occurring in the early menopausal
transition?
A. Stage -3a
B. Stage -3b
C. Stage -2
D. Stage -1
CORRECT ANSWER: C. Stage -2
Rationale: The STRAW +10 (Stages of Reproductive Aging Workshop) criteria define
the early menopausal transition (Stage -2) by persistent differences in menstrual cycle
length of 7 days or more. Stage -3a and -3b represent the late reproductive stage, with -
,3b showing a decrease in cycle length. Stage -1 is the late transition, characterized by
amenorrhea of 60 days or more.
Question 3: A 48-year-old woman presents with symptoms of vulvovaginal
atrophy. She is concerned about systemic absorption. What is the most
appropriate first-line topical treatment for her symptoms, according to NAMS
guidelines?
A. Ospemifene 60 mg daily
B. Prasterone (DHEA) 6.5 mg daily
C. Low-dose vaginal estradiol tablet (10 mcg)
D. Oral conjugated equine estrogens 0.3 mg daily
CORRECT ANSWER: C. Low-dose vaginal estradiol tablet (10 mcg)
Rationale: For genitourinary syndrome of menopause (GSM) without systemic
symptoms, low-dose vaginal estrogen (such as the 10 mcg estradiol tablet, 0.5 g
estradiol cream, or ring) is the first-line treatment. It is highly effective and has minimal
systemic absorption, making it safe for most women. Ospemifene and prasterone are
FDA-approved alternatives but are generally second-line. Oral estrogen is systemic and
not indicated for isolated GSM.
Question 4: A 55-year-old woman is 3 years post-menopausal and asks about
the benefits of hormone therapy (HT) for chronic disease prevention. Based on
the current NAMS position statement, what is the recommendation regarding
HT for primary prevention of coronary heart disease?
A. HT is recommended for primary prevention of CHD in all women over 50
B. HT is not recommended for primary prevention of CHD
C. HT is recommended only if initiated within 10 years of menopause
D. HT is recommended only for women with a family history of CHD
CORRECT ANSWER: B. HT is not recommended for primary prevention of CHD
Rationale: The NAMS position statement clarifies that hormone therapy should not be
used for the primary prevention of coronary heart disease. While the "timing
hypothesis" suggests potential benefits if started early (the "window of opportunity"), the
recommendation against primary prevention stands. However, HT may be considered
for symptom management in recently menopausal women without contraindications,
acknowledging possible coronary benefits in that specific subgroup but not as a
preventive strategy.
Question 5: Which of the following is considered an absolute contraindication
to the use of systemic menopausal hormone therapy?
A. History of deep vein thrombosis (DVT)
B. History of migraine with aura
C. History of hypertension
D. History of hypothyroidism
,CORRECT ANSWER: A. History of deep vein thrombosis (DVT)
Rationale: A history of venous thromboembolism (DVT or pulmonary embolism) is an
absolute contraindication to systemic hormone therapy due to the increased risk of
recurrence. Migraine with aura is a relative contraindication, while hypertension and
hypothyroidism are not contraindications but require monitoring and management.
Question 6: In a 53-year-old woman using a transdermal estradiol patch, what
is the primary advantage of the transdermal route over oral estrogen therapy
concerning venous thromboembolism (VTE) risk?
A. Lower risk of breast cancer
B. Lower risk of VTE due to avoiding first-pass hepatic metabolism
C. Higher efficacy for treating vasomotor symptoms
D. Better protection against osteoporosis
CORRECT ANSWER: B. Lower risk of VTE due to avoiding first-pass hepatic
metabolism
Rationale: Transdermal estrogen avoids the first-pass hepatic effect, which reduces the
production of clotting factors (e.g., prothrombin) and thus lowers the risk of VTE
compared to oral estrogens. This makes the transdermal route a preferred option for
women at elevated VTE risk (e.g., BMI > 30, smokers). It does not lower breast cancer
risk and has similar efficacy for VMS and bone health as oral forms when doses are
equivalent.
Question 7: A 60-year-old woman has been on combined continuous estrogen
and progestin therapy for 5 years. She is concerned about breast cancer risk.
According to NAMS, when should she be counseled to reevaluate her need for
continued hormone therapy?
A. Every 6 months
B. Annually
C. Every 2 years
D. Only when symptoms recur
CORRECT ANSWER: B. Annually
Rationale: NAMS recommends that the need for continued hormone therapy should be
assessed annually, weighing benefits and risks. There is no universal time limit, but the
risks (breast cancer, VTE, stroke) increase with age and duration of use, so annual
reassessment is critical for shared decision-making.
Question 8: Which of the following best describes the effect of the North
American Menopause Society's (NAMS) position on compounded bioidentical
hormone therapy?
A. Compounded hormones are superior to FDA-approved hormones due to their
"natural" composition.
B. Compounded hormones are preferred for women with allergies to standard
, preparations.
C. NAMS cautions against the use of compounded hormones due to lack of FDA
approval, standardized dosing, and safety/efficacy data.
D. NAMS recommends compounded hormones as first-line therapy for all menopausal
symptoms.
CORRECT ANSWER: C. NAMS cautions against the use of compounded
hormones due to lack of FDA approval, standardized dosing, and
safety/efficacy data.
Rationale: NAMS has issued a position statement cautioning against the use of
compounded bioidentical hormone therapy because of concerns regarding lack of
rigorous testing, variable potency, purity concerns, and absence of safety data. FDA-
approved bioidentical hormones (e.g., micronized 17β-estradiol) are preferred for their
consistent quality and proven efficacy.
Question 9: A 50-year-old woman in the late menopausal transition
experiences heavy menstrual bleeding. Which of the following is the most
appropriate initial diagnostic step to rule out endometrial pathology?
A. Empiric progestin therapy
B. Transvaginal ultrasound for endometrial stripe measurement
C. Hysteroscopy
D. Endometrial biopsy
CORRECT ANSWER: B. Transvaginal ultrasound for endometrial stripe
measurement
Rationale: In the evaluation of abnormal uterine bleeding in perimenopausal women,
transvaginal ultrasound is the recommended initial, non-invasive imaging modality to
measure endometrial thickness. An endometrial stripe < 4-5 mm is considered low risk
for malignancy (negative predictive value > 99%) in postmenopausal women, and a
threshold of ≤ 11 mm is often used for perimenopausal women. An endometrial biopsy
is indicated if the stripe is thickened or if risk factors persist.
Question 10: A postmenopausal woman on oral micronized progesterone (100
mg) reports significant drowsiness. What is the most appropriate management
strategy?
A. Discontinue the progesterone entirely
B. Switch to a synthetic progestin (e.g., medroxyprogesterone acetate)
C. Advise taking the dose at bedtime
D. Increase the dose to overcome the effect
CORRECT ANSWER: C. Advise taking the dose at bedtime
Rationale: Drowsiness is a common side effect of micronized progesterone due to its
metabolite, allopregnanolone, which has GABAergic effects. Taking the medication at
bedtime is an effective strategy to manage this side effect, converting it into a benefit
